IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.472
AS - Asia 7.059
EU - Europa 5.457
SA - Sud America 963
Continente sconosciuto - Info sul continente non disponibili 660
AF - Africa 238
OC - Oceania 20
Totale 25.869
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.969
CN - Cina 2.893
SG - Singapore 1.654
IE - Irlanda 1.104
IT - Italia 960
HK - Hong Kong 893
BR - Brasile 684
VN - Vietnam 659
RU - Federazione Russa 619
DE - Germania 515
FI - Finlandia 494
FR - Francia 491
UA - Ucraina 428
GB - Regno Unito 305
SE - Svezia 229
CA - Canada 213
IN - India 204
BD - Bangladesh 187
ZA - Sudafrica 113
AR - Argentina 99
MX - Messico 79
JP - Giappone 77
IQ - Iraq 61
TR - Turchia 61
NL - Olanda 57
ID - Indonesia 56
PL - Polonia 48
CO - Colombia 42
PK - Pakistan 41
CR - Costa Rica 35
EC - Ecuador 35
ES - Italia 35
BE - Belgio 32
VE - Venezuela 32
JM - Giamaica 31
MA - Marocco 27
SA - Arabia Saudita 27
PH - Filippine 25
MY - Malesia 24
NI - Nicaragua 22
AT - Austria 21
IL - Israele 20
JO - Giordania 20
AU - Australia 19
UZ - Uzbekistan 19
EG - Egitto 18
CL - Cile 17
LT - Lituania 17
PY - Paraguay 17
TT - Trinidad e Tobago 17
HN - Honduras 16
TN - Tunisia 16
IR - Iran 15
KE - Kenya 15
AE - Emirati Arabi Uniti 14
SV - El Salvador 14
CZ - Repubblica Ceca 13
BO - Bolivia 12
KR - Corea 12
AZ - Azerbaigian 11
CW - ???statistics.table.value.countryCode.CW??? 11
PE - Perù 11
BB - Barbados 10
GP - Guadalupe 10
GT - Guatemala 10
PR - Porto Rico 10
DK - Danimarca 9
KZ - Kazakistan 9
RO - Romania 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
EE - Estonia 8
EU - Europa 8
MD - Moldavia 8
NP - Nepal 8
PA - Panama 8
AL - Albania 7
CH - Svizzera 7
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
LB - Libano 7
TH - Thailandia 7
BA - Bosnia-Erzegovina 6
ET - Etiopia 6
OM - Oman 6
PS - Palestinian Territory 6
SN - Senegal 6
BH - Bahrain 5
CU - Cuba 5
CY - Cipro 5
LV - Lettonia 5
SC - Seychelles 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
CI - Costa d'Avorio 4
GY - Guiana 4
KW - Kuwait 4
NG - Nigeria 4
QA - Qatar 4
Totale 25.163
Salva come PNG Salva come JPEG
Città #
San Jose 1.238
Dublin 1.100
Chandler 1.019
Ashburn 937
Singapore 908
Hong Kong 876
Dallas 723
Council Bluffs 682
Jacksonville 581
Beijing 535
Nanjing 523
Boardman 365
Los Angeles 289
Lauterbourg 241
New York 227
Princeton 223
Ho Chi Minh City 216
Lawrence 202
Nanchang 201
Wilmington 186
Hebei 172
Hanoi 160
Santa Clara 158
Helsinki 157
Milan 149
Changsha 144
Medford 144
Shenyang 140
Munich 132
Ann Arbor 130
Jiaxing 124
Buffalo 122
Shanghai 110
Tianjin 106
Redondo Beach 104
Moscow 102
Johannesburg 90
Hangzhou 79
Rome 77
Columbus 76
Pavia 76
São Paulo 74
Tokyo 68
Seattle 57
Orem 55
Montreal 54
Turku 52
Chicago 46
San Francisco 46
The Dalles 46
Pune 45
Toronto 45
Brooklyn 43
Chennai 43
Falkenstein 42
Frankfurt am Main 42
Atlanta 38
Woodbridge 38
Falls Church 37
Stockholm 36
Warsaw 36
Washington 35
Da Nang 33
Norwalk 33
Nuremberg 31
Brussels 30
North Bergen 29
Phoenix 29
Denver 28
Guangzhou 28
Houston 28
Mexico City 28
Verona 28
Naples 27
Paris 27
London 26
Baghdad 23
Manchester 23
Ankara 22
Haiphong 21
Managua 21
Poplar 21
Belo Horizonte 20
Zhengzhou 20
Brasília 19
Dhaka 19
San José 19
Boston 18
Philadelphia 18
Amsterdam 17
Bari 17
Fairfield 17
Kingston 17
Amman 16
Queens 16
Tashkent 16
Des Moines 15
Brescia 14
Figino 14
Florence 14
Totale 15.644
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 204
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 200
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 194
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2) 191
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 177
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 176
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 176
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 168
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 167
An insidious presentation of splenic marginal zone lymphoma 165
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 162
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders 161
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 159
Blast phase of essential thrombocythemia: A single center study. 156
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 156
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 156
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 154
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 150
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 147
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 146
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 143
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 142
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 142
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 139
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 137
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 136
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 136
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 135
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 134
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 133
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 133
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 132
Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer 132
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 131
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 130
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 128
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 128
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 127
Diagnosis and management of prefibrotic myelofibrosis. 127
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 126
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 125
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 125
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network 125
A young woman with microcytic anemia and hypertransaminasemia 124
Everolimus in diffuse large B-cell lymphomas 123
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice 122
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 121
Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy 121
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 119
Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas 119
Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma 118
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 118
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 118
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 118
Antiviral therapies for managing viral hepatitis in lymphoma patients 117
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 116
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 116
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 116
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. 115
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 115
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 114
Retrospective Investigation of Human Papillomavirus Cervical Infection and Lymphoma Incidence: A Clinical and Pathological Evaluation 114
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 113
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 113
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network 113
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 113
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 112
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 112
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 112
A paraumbilical lymphomatous mass 111
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 111
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center 111
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 110
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 109
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 109
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 109
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 109
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 109
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 108
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 107
Role of the molecular staging and response in the management of follicular lymphoma patients 106
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 106
Genetic characterization and clinical features of helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma 105
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 105
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 105
Double expressor and double/triple hit status among primary cutaneous diffuse large B cell lymphoma: A comparison between leg type and NOS Subtypes 105
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 105
Transient response of myeloma clone to pamidronate therapy 103
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial 103
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 103
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 102
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 101
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 101
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 101
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 100
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 99
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins 99
Mantle cell lymphoma of mucosa-associated lymphoid tissue: A european mantle cell lymphoma network study 99
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 98
Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study 98
Totale 12.690
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.601
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022925 0 0 0 15 38 55 19 56 53 40 141 508
2022/20232.990 277 196 21 239 279 318 27 177 1.257 28 111 60
2023/20241.404 147 234 60 97 107 395 34 84 12 53 74 107
2024/20253.794 116 269 74 88 78 233 349 242 846 136 466 897
2025/20269.022 637 663 1.000 1.009 956 351 1.818 325 798 700 479 286
2026/20273.322 352 732 821 1.417 0 0 0 0 0 0 0 0
Totale 25.869